Skip to main content
padlock icon - secure page this page is secure

Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b

Buy Article:

$52.00 + tax (Refund Policy)

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by various types of immunological abnormalities including circulating and tissue‐fixed autoantibodies reactive with autoantigens. The mechanism that can explain the production of these antibodies is unclear. Here we address the binding specificity of SLE autoantibodies with recombinant alpha interferon 2b (hrIFN α‐2b), commercially available interferon (IFN α‐2b), and the gene (cIFN α‐2b) encoding this interferon. hrIFN α‐2b showed higher binding with naturally occurring SLE autoantibodies as compared to IFN α‐2b (p < 0.05) or cIFN α‐2b gene (p < 0.001) as assessed by direct binding, inhibition ELISA, and quantitative precipitin titration. The relative affinity of SLE autoantibodies for hrIFN α‐2b, IFN α‐2b, and cIFN α‐2b gene was in the order of 1.13 × 10−7, 1.38 × 10−6, and 1.22 × 10−6, respectively. hrIFN α‐2b is shown to have unique epitopes that would explain the possible antigenic role of hrIFN α‐2b in the generation of SLE autoantibodies. Anti‐hrIFN α‐2b antibodies have been shown to represent an alternative immunological probe for the estimation of interferon alpha 2b in the serum of SLE patients.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ELISA; Recombinant interferon alpha 2b (hrINF α‐2b); affinity; antibodies; systemic lupus erythematosus

Document Type: Research Article

Publication date: December 1, 2015

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more